Please login to the form below

Not currently logged in
Email:
Password:

FDA grants orphan status for two drugs

Senesco has won US orphan drug status for a multiple myeloma drug, while Optimer has won orphan status for a potential drug for paediatric CDI

Senesco Technologies has won orphan drug status from the US Food and Drug Administration for a multiple myeloma drug, while Optimer has been granted US orphan status for a potential treatment for paediatric Clostridium difficile infection (CDI).

Orphan drug status, which is designed to encourage the development of treatments for diseases affecting fewer than 200,000 Americans, carries with it a number of benefits to the drug sponsor, including tax credits, access to grant funding for clinical trials, accelerated FDA approval, seven years of marketing exclusivity after drug approval, and potential exemption from the FDA's prescription drug application fee.

Senesco's SNS01-T multiple myeloma drug, the company's lead product candidate, is about to enter clinical studies. The drug was developed using proprietary technology that regulates programmed cell death, or apoptosis.

Optimer's drug for paediatric CDI, called fidaxomicin, is also the company's lead product candidate. The drug has completed phase III trials in adults, and marketing applications have been filed in the US and the EU seeking approval for fidaxomicin for the treatment of CDI and for the reduction of recurrences in adult patients.

Fidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase. Currently, vancomycin is the only FDA-approved drug for CDI, although metronidazole is used off-label. About 30 per cent of CDI patients who initially respond to these treatments have a clinical recurrence once drug treatment ends, according to Optimer.

5th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics